48,460
edits
Difference between revisions of "Classification of urothelial carcinoma by immunohistochemistry"
Jump to navigation
Jump to search
Classification of urothelial carcinoma by immunohistochemistry (view source)
Revision as of 18:08, 8 March 2024
, 8 Marchno edit summary
(→Sign out: sm tweak) |
|||
| (4 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
==General== | ==General== | ||
*A large meta-analysis showed two markers (CK5/6, GATA3) can subclassify ~90% of urothelial carcinoma into prognostic groups.<ref>{{cite journal |authors=Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B |title=Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use |journal=EBioMedicine |volume=12 |issue= |pages=105–117 |date=October 2016 |pmid=27612592 |pmc=5078592 |doi=10.1016/j.ebiom.2016.08.036 |url=}}</ref> | *A large meta-analysis showed two markers (CK5/6, GATA3) can subclassify ~90% of urothelial carcinoma into prognostic groups.<ref name=pmid27612592>{{cite journal |authors=Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B |title=Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use |journal=EBioMedicine |volume=12 |issue= |pages=105–117 |date=October 2016 |pmid=27612592 |pmc=5078592 |doi=10.1016/j.ebiom.2016.08.036 |url=}}</ref> | ||
===A simple classification of urothelial carcinoma by immunohistochemistry=== | ===A simple classification of urothelial carcinoma by immunohistochemistry=== | ||
| Line 18: | Line 18: | ||
*GATA3 ''positive'' and CK5/6 ''positive'' cases are classified as ''luminal''.<ref name=pmid34103388/> | *GATA3 ''positive'' and CK5/6 ''positive'' cases are classified as ''luminal''.<ref name=pmid34103388/> | ||
*GATA3 ''negative'' and CK5/6 ''negative'' are ''unclassified''.<ref name=pmid34103388/> | *GATA3 ''negative'' and CK5/6 ''negative'' are ''unclassified''.<ref name=pmid34103388/> | ||
Additional note: | |||
*[[CK20]] is considered an alternate luminal marker.<ref name=pmid28632777 >{{cite journal |authors=Sikic D, Keck B, Wach S, Taubert H, Wullich B, Goebell PJ, Kahlmeyer A, Olbert P, Isfort P, Nimphius W, Hartmann A, Giedl J |title=Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis |journal=PLoS One |volume=12 |issue=6 |pages=e0179602 |date=2017 |pmid=28632777 |pmc=5478149 |doi=10.1371/journal.pone.0179602 |url=}}</ref> | |||
===Prognosis=== | |||
'''B'''asal is '''b'''ad.<ref name=pmid27612592>{{cite journal |authors=Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B |title=Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use |journal=EBioMedicine |volume=12 |issue= |pages=105–117 |date=October 2016 |pmid=27612592 |pmc=5078592 |doi=10.1016/j.ebiom.2016.08.036 |url=}}</ref> | |||
'''L'''uminal is '''l'''ower risk. | |||
==IHC== | ==IHC== | ||